Shuttle Pharmaceuticals Holdings, Inc. Uncategorized Contracts & Agreements
27 Contracts & Agreements
- Form of Pre-Funded Warrants (Filed With SEC on October 18, 2024)
- Form of Common Warrants (Filed With SEC on October 18, 2024)
- Form of Common Warrants (Filed With SEC on October 17, 2024)
- Work Order, dated August 8, 2024, between Shuttle Pharmaceuticals, Inc. and Theradex Systems, Inc (Filed With SEC on August 14, 2024)
- Amendment Agreement, dated August 6, 2024, between Shuttle Pharmaceuticals Holdings, Inc., Shuttle Pharmaceuticals, Inc. and Alto Opportunity Master Fund, SPC Segregated Master... (Filed With SEC on August 7, 2024)
- Amendment No. 1 to the Amendment Agreement, dated June 4, 2023, by and between Shuttle Pharmaceuticals Holdings, Inc., Shuttle Pharmaceuticals, Inc. and Alto Opportunity Master... (Filed With SEC on June 5, 2023)
- Amendment Agreement, dated May 10, 2023, by and between Shuttle Pharmaceuticals Holdings, Inc., Shuttle Pharmaceuticals, Inc. and Alto Opportunity Master Fund, SPC Segregated... (Filed With SEC on May 11, 2023)
- Material Transfer Agreement, dated March 21, 2023, between Shuttle Pharmaceuticals, Inc. and Georgetown University (Filed With SEC on March 22, 2023)
- Research Agreement, dated March 16, 2023, between Shuttle Pharmaceuticals, Inc. and Georgetown University (Filed With SEC on March 22, 2023)
- Letter Agreement, dated March 11, 2023, between Shuttle Pharmaceuticals Holdings, Inc. and Alto Opportunity Master Fund, SPC Segregated Portfolio B, as Collateral Agent (Filed With SEC on March 15, 2023)
- Amended and Restated Insider Trading Policy, effective March 10, 2023 (Filed With SEC on March 15, 2023)
- Form of Director Letter Agreement (Filed With SEC on February 22, 2023)
- Form of Director Offer Letter (Filed With SEC on November 1, 2022)
- Manufacturing Agreement, dated September 14, 2022, between Shuttle Pharmaceuticals, Inc. and TCG GreenChem, Inc (Filed With SEC on September 19, 2022)
- First Amendment to Non-Disclosure, Evaluation and Option Agreement, dated November 30, 2019, between Shuttle Pharmaceutical, Inc. and University of Virginia Licensing & Ventures... (Filed With SEC on June 3, 2022)
- Non-Disclosure, Evaluation and Option Agreement, dated May 30, 2019, between Shuttle Pharmaceuticals, Inc. and University of Virginia Licensing & Ventures Group (Filed With SEC on June 3, 2022)
- Director Offer Letter, dated December 2, 2020, between Chris Senanayake and Shuttle Pharmaceuticals Holdings, Inc (Filed With SEC on June 3, 2022)
- SBIR Phase II Contract #75N9101C00031, dated September 6, 2019, between Shuttle Pharmaceuticals, Inc. and National Institute of Health National Cancer Institute (Filed With SEC on June 3, 2022)
- SBIR Contract #HHSN261201800016C/75N91018C00016 Agreement between Shuttle Pharmaceuticals, LLC and National Institute of Health National Cancer Institute (Filed With SEC on June 3, 2022)
- Sublicense Agreement, dated February 15, 2019, between Shuttle Pharmaceuticals Inc. and Propagenix, Inc (Filed With SEC on June 3, 2022)
- Subaward Agreement dated October 28, 2014 between Shuttle Pharmaceuticals, LLC and LifeSpan/Rhode Island Hospital (Filed With SEC on June 3, 2022)
- Form of Letter Agreement with Director (Filed With SEC on June 3, 2022)
- Material Transfer Agreement, dated April 25, 2017, between Shuttle Pharmaceuticals, Inc. and George Washington University (Filed With SEC on June 3, 2022)
- SBIR Contract #HHSN261600038C dated September 19, 2016 between Shuttle Pharmaceuticals, LLC. and National Institute of Health National Cancer Institute (Filed With SEC on June 3, 2022)
- SBIR Contract #HHSN261201600027C, dated September 19, 2016, between Shuttle Pharmaceuticals, LLC and National Institute of Health National Cancer Institute (Filed With SEC on June 3, 2022)
- SBIR Contract #HHSN261201400013C Amendment of Solicitation/Modification of Contract, dated August 3, 2015, between Shuttle Pharmaceuticals, LLC and National Institute of Health... (Filed With SEC on June 3, 2022)
- SBIR Contract #HHSN261201400013C, dated September 19, 2014, between Shuttle Pharmaceuticals, LLC and National Institute of Health National Cancer Institute (Filed With SEC on June 3, 2022)
